Gullain Barre Syndrome: Rare side effect of Covid 19 vaccine?

It is observed that there is an  increased risk of GBS following COVID 19 vaccination. WHO Global Advisory Committee on Vaccine Safety (GACVS) discusses rare reports of Guillain-Barré Syndrome (GBS) following vaccination with the Janssen and AstraZeneca COVID-19 vaccines. 

GACVS Committee Conclusion

• Rare cases of GBS have been reported following vaccinations with adenovirus vector COVID-19 vaccines.

• Increased reports of GBS have not been observed following mRNA COVID-19 vaccines.

Although they could not confirm nor rule out an association with the vaccine . GBS will be listed as a very rare side effect of COVID-19 Vaccine Janssen. Therefore warning is given to raise awareness among healthcare professionals and people taking the vaccine.

What is Guillain-Barré syndrome (GBS) ?

GBS is a rare, autoimmune disorder in which a person's own immune system damages the nerves , causing muscle weakness and sometimes paralysis.

Symptoms

• Muscle weakness, 
• Difficulty in walking
• Weakness of the arms and legs
• Tingling sensation in arms and legs
• Double Vision
• Difficulty speaking, swallowing, breathing 
• Loss of bowel and bladder control.

Most people recover fully, but some have permanent nerve damage.

GACVS Committee Recommendation

For Vaccinated People

• Symptoms of GBS ranges from mild weakness to more severe paralysis. 

• Most people recover fully from symptoms but few experience some degree of weakness.

• Seek immediate medical attention if you develop symptoms of GBS within 42 days of vaccination.

 For Healthcare Professionals

• Be alert on the signs and symptoms of GBS

• Ensure diagnosis and initiate supportive care and treatment. 

WHO constantly monitors all Covid 19 vaccine and will continue to manage potential risks and will update any advice as necessary. Moreover the benefits of Covid 19 vaccines outweigh the risks.